Jeenah Moon/Getty Images News
Viking Therapeutics (NASDAQ:VKTX) and other developers of oral weight loss drugs traded sharply higher on Tuesday after Pfizer (NYSE:PFE) CEO Albert Bourla indicated plans to seek deals to add cardiometabolic drugs, including obesity therapies, to replenish the company’s pipeline.
Other notable